Free Trial
NASDAQ:MURA

Mural Oncology 3/11/2025 Earnings Report

Mural Oncology logo
$2.61 +0.01 (+0.38%)
Closing price 04:00 PM Eastern
Extended Trading
$2.57 -0.04 (-1.57%)
As of 06:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mural Oncology EPS Results

Actual EPS
-$2.01
Consensus EPS
-$1.96
Beat/Miss
Missed by -$0.05
One Year Ago EPS
-$3.57

Mural Oncology Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Mural Oncology Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Mural Oncology's next earnings date is estimated for Tuesday, May 13, 2025, based on past reporting schedules.

Conference Call Resources

Mural Oncology Earnings Headlines

Parkwood Master Fund Ltd - Form 8.3 - Mural Oncology Plc
Form 8.3 - Mural Oncology plc
Massive new energy source found in Utah
NEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millions of years. And both grizzled oilmen and clean energy supporters love it: Energy Secretary Chris Wright called it "an awesome resource," while Warren Buffett, Jeff Bezos, Mark Zuckerberg, and Bill Gates are all directly invested.
Form 8.3 - The Vanguard Group, Inc.: Mural Oncology plc
See More Mural Oncology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Mural Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mural Oncology and other key companies, straight to your email.

About Mural Oncology

Mural Oncology (NASDAQ:MURA), a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.

View Mural Oncology Profile

More Earnings Resources from MarketBeat